Addex Therapeutics Ltd ADXN
NASDAQ
| 03/31/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.29% | -33.29% | -67.47% | -11.46% | 53.60% |
| Total Depreciation and Amortization | 420.83% | 420.83% | -90.04% | -95.80% | -29.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 61.39% | 61.39% | 61.79% | 2.69% | 164.55% |
| Change in Net Operating Assets | -1,974.74% | -1,974.74% | -60.96% | 17.73% | -103.01% |
| Cash from Operations | -46.70% | -46.70% | -2,792.91% | -44.64% | 73.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 76.24% | 1,516.98% | -- |
| Cash from Investing | -- | -- | 76.24% | 1,204.41% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 11.11% | 11.11% | -5.56% | 18.18% | 97.30% |
| Issuance of Common Stock | -- | -- | 1,417.86% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -103.41% | -103.41% | 82.14% | -135.29% | 10,080.00% |
| Cash from Financing | -23.39% | -23.39% | 4,835.00% | 75,316.67% | -42.08% |
| Foreign Exchange rate Adjustments | 77.46% | 77.46% | -104.95% | 94.60% | -115.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.28% | -56.28% | -7,978.82% | 71.96% | 77.56% |